Table 5.
Univariate and multivariate analysis of clinicopathologic variables associated with progression-free survival
| Hazard ratio (univariate) | P value (univariate) | P value (multivariate) | |
|---|---|---|---|
| Sex (male versus female) | 0.93 | .70 | – |
| Age | 1.08 per 10 years | .36 | – |
| Grade | < .01 | – | |
| Grade 1 versus grade 2 | 2.25 | < .01 | – |
| Grade 1 versus grade 3 | 5.78 | < .01 | – |
| Primary Ki-67 | 1.58 per 5% | < .01 | – |
| Met Ki-67 | 1.35 per 5% | < .01 | – |
| Overall Ki-67 | 1.41 per 5% | < .01 | < .01 |
| Mitotic rate | 1.04 | .11 | – |
| Lymphovascular nvasion | 1.80 | .11 | – |
| Perineural nvasion | 1.19 | .57 | – |
| Percent liver replacement | 1.27 per 10% | < .01 | .04 |
| NETLMs preop | 1.18 per 10 lesions | < .01 | – |
| Multifocality | 0.77 | .30 | – |
| Primary site (SB versus pancreas) | 0.62 | .03 | – |
| Number of lesions treated | 1.06 per 10 lesions | .66 | – |
| Percent tumor debulked | 0.79 per 10% | < .01 | < .01 |
| ≥70% versus <70% debulking | 0.31 | < .01 | – |
| >90% versus ≤90% debulking | 0.36 | < .01 | – |
| >90% versus 70–90% debulking | 0.48 | < .01 | – |
| Surgery before 2010 | 0.76 | .23 | – |
| Primary resected | 0.61 | .02 | < .01 |
| Primary size (largest dimension) | 1.09 per 1 cm | .07 | – |
| Nonsurgical treatments | – | ||
| Somatostatin analog preop | 1.82 | < .01 | – |
| Somatostatin analog postop | 1.00 | 1.0 | – |
| Systemic therapy | 3.08 | < .01 | – |
| Hepatic artery embolization | 1.71 | < .01 | – |
| Peptide receptor radionucleotide therapy | 1.56 | .06 | – |